Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women.
OBJECTIVE
This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women' Interagency HIV Study.


METHODS
Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability.


RESULTS
Before the availability of HAART, the cohort' likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American.


CONCLUSIONS
After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women' access to the most effective types of therapy.
Cook
Judith A
JA
Mental Health Services Research Program, Department of Psychiatry, University of Illinois at Chicago, 104 S Michigan Ave, Suite 900, Chicago, IL 60603, USA. cook@ripco.com
Cohen
Mardge H
MH
Grey
Dennis
D
Kirstein
Lynn
L
Burke
Jane
J
Anastos
Kathryn
K
Palacio
Herminia
H
Richardson
Jean
J
Wilson
Tracey E
TE
Young
Mary
M
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D004493:Education; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D018119:Stavudine / Q000627:therapeutic use; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D018119:Stavudine